$558.76+4.86% · 3M
Moving avg
1W-4.76%
1M+0.31%
3M+5.67%
6M-11.22%
YTD-16.60%
1Y-14.56%
3Y+10.06%
5Y-17.28%
52-week range
$518.5516% of range$769.98
Company health
Value0/6
Growth5/6
Profitability6/6
Health3/6
Dividend0/6
Bull vs bear
Strengths
- Analysts see 34% upside to a $748 target
- Analyst consensus is "Buy"
- Strong 25% net margin
- High return on equity (7087%)
- Revenue compounding 10% a year
Risks
- More volatile than the market (beta 1.5)
Key statistics
Valuation
Market cap
$44.08B
Enterprise value
$43.84B
P/E ratio (TTM)
39.82x
P/S ratio (TTM)
9.66x
EV/EBITDA
28.13x
Per share & returns
EPS (TTM)
$13.67
Dividend yield
0.00%
Beta (1Y)
1.55
30-day change
+0.31%
Trading
Volume (24h)
176.85K
Previous close
$570.58
Shares outstanding
78.88M
About IDEXX Laboratories, Inc.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Exchange
NASDAQ
Symbol
IDXX
IDEXX Laboratories, Inc. is a large-cap healthcare company in the Medical - Diagnostics & Research industry. Its shares are listed on NASDAQ (United States) and trade under the ticker IDXX.
Frequently asked questions
What is IDEXX Laboratories, Inc.'s market cap?
IDEXX Laboratories, Inc. (IDXX) has a market capitalization of $44.08B.
What is IDEXX Laboratories, Inc.'s P/E ratio?
IDEXX Laboratories, Inc. trades at a price-to-earnings (P/E) ratio of 39.82.
What exchange does IDXX trade on?
IDXX trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,216.03-0.35%
$1.15T cap
Johnson & JohnsonJNJ
$261.33+0.18%
$629.78B cap
AbbVie Inc.ABBV
$250.78+0.81%
$443.08B cap
UnitedHealth Group IncorporatedUNH
$402.12-0.86%
$365.18B cap
Roche Holding AGSWX: ROP
CHF 362.30-0.88%
$354.73B cap
Merck & Co., Inc.MRK
$134.53+1.21%
$332.26B cap
Novartis AGSWX: NOVN
CHF 123.74-0.37%
$289.30B cap
AstraZeneca PLCLON: AZN
£117.08+0.05%
$245.01B cap